

No.					
1	10-021-2			Stage b UFT/Leucovorin TS-1/Oxaliplatin	24 4 7
2	11-129			PEG-IFN -2b+Ribavirin+Telaprevir	24 4 7
3	11-130			FAST VSRAD	24 4 7
4	11-131			JCOG0905 Ifosfamide	24 4 7
5	12-001			(MRD) WT1	24 4 12
6	12-002				24 4 12
7	12-003			QOL MY	24 4 18
8	12-004			ST (CAPITAL-RCT) A CYP2C19	24 4 19
9	12-005			H.pylori MALT	24 4 19
10	11-119			Oxaliplatin,bevacizumab(BV) KRAS FOLFIRI+BV FOLFIRI+Panitumumab(Pmab) vs	24 4 20
11	11-124			ADPKD QOL	24 4 20
12	11-123				24 4 24
13	12-007			(JMOG:Japanese Musculoskeletal Oncology Group) thromboembolism cohort study for sarcoma:VTECS) (Venous	24 4 24
14	11-120			Oxaliplatin,bevacizumab(BV) KRAS FOLFIRI+BV FOLFIRI+Panitumumab(Pmab) vs	24 4 25
15	11-121				24 4 25
16	10-077-2			Stage / mFOLFOX6	24 4 28
17	11-054-2			DAPT Endeavor ZES (OPERA Study)	24 4 28
18	12-008			Index	24 4 28
19	12-009			atHome	24 4 28
20	12-010				24 4 28
21	12-011				24 4 28

No.					
1	11-113			(CTCs)	24 5 7
2	11-118			HER2 65	24 5 7
3	12-012			VTE	24 5 8
4	12-013				24 5 8
5	12-006			CKD ARB Intermittent removal of thiazide diuretics for treatment of hypertension in CKD patients study (INTERVAL study)	24 5 16
6	07-021-2				24 5 22
7	07-095-2			Menkes	24 5 22
8	08-114-2			Menkes occipital horn	24 5 22
9	11-104-2			ATSIM	24 5 22
10	12-014			Menkes Wilson	24 5 22
11	12-015				24 5 22
12	12-016				24 5 22
13	10-137-3			FOLFIRI panitumumab FOLFOX	24 5 23
14	12-017				24 5 23
15	08-019-3				24 5 28
16	09-027-3			/ 5-fluorouracil(5-FU)/levofolinate calcium(I-LV)+oxaliplatin(L-OHP)+bevacizumab(BEV) 5FU/I-LV+irinotecan(CPT-11)+BEV (WJOG 4407G)	24 5 28
17	11-012-3			Cisplatin 1mg Palonosetron0.75 Granisetron (TRIPLE)	24 5 28



No.					
1	09-026-6			B/	24 7 4
2	11-011-2				24 7 4
3	11-082-2			MRI	24 7 4
4	12-038			1st line TKI	24 7 5
5	12-040			(PTH)	24 7 10
6	12-041			(GERD) (PPI)	24 7 10
7	11-080-3			LDL-C	24 7 11
8	12-042			KRAS mFOLFOX6 mFOLFOX6+	24 7 17
9	12-043			Stage UFT/LV	24 7 17
10	12-044			<i>Clostridium difficile</i>	24 7 17
11	08-056-2			(CKD)	24 7 24
12	12-045			(Hereditary Spastic Paraplegia:HSP)	24 7 24
13	12-046			Marin Amat	24 7 24
14	12-047				24 7 24
15	12-018				24 7 25
16	12-048				24 7 25
17	09-124-2				24 7 31
18	10-036-2				24 7 31
19	12-049			BioPlex2200 IgG 1 2	24 7 31
20	12-050			AML-D11	24 7 31
21	12-051				24 7 31

No.					
1	12-052				24 8 2
2	11-066-3			(ADPKD)	24 8 7
3	12-029				24 8 9
4	12-038		2	DPP-4	24 8 9
5	12-053				24 8 9
6	12-054			(JCOG 1110-A)	24 8 9
7	12-055				24 8 9
8	12-034				24 8 13
9	12-056			JHEQ	24 8 14
10	12-057				24 8 14
11	12-060				24 8 20
12	12-061				24 8 20
13	12-062			SPECT (J-ACCESS )	24 8 21
14	12-063				24 8 21
15	11-119-2			Oxaliplatin,bevacizumab(BV) KRAS FOLFIRI+BV FOLFIRI+Panitumumab(Pmab) vs	24 8 24
16	11-120-2			Oxaliplatin,bevacizumab(BV) KRAS FOLFIRI+BV FOLFIRI+Panitumumab(Pmab) vs	24 8 24
17	12-064			KRAS mFOLFOX6 mFOLFOX6	24 8 24
18	12-065				24 8 24
19	12-066			(FILTRAP™) (The VAMPIRE 3 Study)	24 8 25
20	12-067				24 8 28
21	12-068			PCI Trial of Atheroma Regression Evaluated with Integrated Backscatter Intravascular Ultrasound by administering Sitagliptin.(TRUST Study)	24 8 28
22	12-069				24 8 28
23	12-070				24 8 31

No.					
1	12-071				24 9 1
2	12-072			OATP1B3	24 9 1
3	12-074			mFOLFOX6 KRAS RO	24 9 6
4	10-133-2			(J-LESSON)	24 9 8
5	12-075			Stage mFOLFOX6 XELOX 5-FU	24 9 8
6	12-076			COL4A5	24 9 10
7	09-081-2			RNA	24 9 12
8	12-077			3T-MRIT1	24 9 12
9	11-003-2			QOL	24 9 13
10	11-016-3			ICS ICS/LABA (Evidence for Leading Updated Treatment using ICS/LABA Combination: EVOLUTION Study)	24 9 13
11	12-078				24 9 24
12	12-079				24 9 24
13	12-080				24 9 24
14	12-081			(HUVEC)	24 9 29

No.						
1	12-082			12	(LCH)	LCH- 24 10 2
2	12-083					24 10 2
3	11-066-4				(ADPKD)	24 10 10
4	11-097-3					24 10 10
5	12-084				QOL	24 10 10
6	12-085			Stage mFOLFOX6	XELOX	5-FU 24 10 10
7	12-086			Stage mFOLFOX6	XELOX	5-FU 24 10 10
8	12-087			J-HIS J-HIS2		24 10 10
9	12-088				(CXCR4)	1 24 10 10
10	12-089				(BV)	CapeOX 24 10 10
11	12-073					24 10 15
12	12-091			3		24 10 15
13	12-092					24 10 15
14	12-093				(PREDICT)	24 10 15
15	12-094				Aquala®	24 10 15
16	12-095				2012	24 10 16
17	12-097			CCR5	maraviroc	HIV 24 10 16
18	12-058			QOL	3	24 10 17
19	12-059				QOL	3 24 10 17
20	12-098					24 10 17
21	11-080-4			LDL-C		24 10 20
22	12-100				2	XELIRI 24 10 20
23	12-101			VerifyNow Aspirin	VerifyNow P2Y12	24 10 20

No.					
24	12-102			Oxaliplatin	24 10 20
25	12-103			5S- KAIZEN- TOM 5S	24 10 24
26	12-104				24 10 24
27	12-105				24 10 24
28	12-106				24 10 24
29	12-107				24 10 24
30	10-032-4			3 TS-1 5	24 10 31
31	12-108			IgA	24 10 31



No.					
1	10-050-4			LDL-C versus Intensive Statin Therapy for Hypercholesterolemic Patients with Diabetic Retinopathy	EMPATHY Standard 24 11 6
2	11-701			DNAR	24 11 6
3	12-110				24 11 6
4	12-111				24 11 6
5	12-112			ANCA	24 11 6
6	12-113			EGFR KRAS codon G13D BSC(Best Supportive Care) Cetuximab(Erbitux) Irinotecan+Cetuximab(Erbitux)	24 11 6
7	12-115				24 11 7
8	10-057-3				24 11 13
9	12-070-2				24 11 13
10	12-116				24 11 13
11	12-118				24 11 13
12	12-078-2				24 11 19
13	12-060-2				24 11 21
14	12-103-2			5S- KAIZEN- TOM	5S 24 11 21
15	12-121				24 11 21
16	12-122			Kanagawa Aquaresis Investigators Trial of Tolvaptan on Heart Failure Patients with Renal Impairment (K-STAR)	24 11 21
17	12-090				24 11 22
18	12-101-2			VerifyNow Aspirin	VerifyNow P2Y12 24 11 27
19	12-096				(Pain Vision) 24 11 29
20	12-123				non-codingRNA 24 11 30
21	12-124			AM)	ACS (NCVC- 24 11 30

No.					
1	12-125				24 12 4
2	12-126				24 12 4
3	12-127				24 12 4
4	10-135-3			(WJOG5910L)	24 12 7
5	12-128			E (VPS)	24 12 7
6	12-129				24 12 7
7	12-130				24 12 7
8	12-131				24 12 7
9	12-132				24 12 7
10	12-133				24 12 7
11	12-114			L/N Ca Non N Ca (J-CIRCLE 2)	24 12 8
12	12-117				24 12 8
13	12-134			TKI Side Effects Low-Grade Side Effects	24 12 14
14	12-135			3	24 12 14
15	12-136			S-1	24 12 14
16	12-137				24 12 14
17	12-138				24 12 14
18	12-139			B ALL-B12	24 12 17
19	12-052-2				24 12 22
20	10-060-2				24 12 25
21	12-007-2			(JMOG:Japanese Musculoskeletal Oncology Group) (Venous thromboembolism cohort study for sarcoma:VTECS)	24 12 25
22	12-140				24 12 25
23	12-141			JCOG0304 2 Ifosfamide,Adriamycin	24 12 25

No.					
24	12-142				24 12 27
25	12-143				24 12 27
26	12-109				24 12 28

No.					
1	08-056-3			(CKD)	25 1 7
2	12-144				25 1 7
3	12-145				25 1 7
4	12-120				25 1 8
5	12-147			FOLFOX (ISR) /	25 1 9
6	12-148				25 1 9
7	12-149				25 1 15
8	12-150				25 1 15
9	12-151				25 1 16
10	12-153			CAPTURE	25 1 19
11	12-154			T QOL	25 1 19
12	12-155			HER2 (POTENT) S-1	25 1 23
13	12-156			in-out	25 1 23
14	12-157			5-fluorouracil(5-FU) mRNA	25 1 23
15	12-158				25 1 23
16	12-159			CT CT	25 1 23
17	12-119			(VCS:Vasculaire Compression System)	25 1 28
18	12-160				25 1 28

No.					
1	12-006-2			CKD ARB Intermittent removal of thiazide diuretics for treatment of hypertension in CKD patients study (INTERVAL study)	25 2 6
2	12-096-2			(Pain Vision)	25 2 6
3	12-099			cuffscats	25 2 7
4	12-162				25 2 8
5	12-163			T3 T4 Stage / mFOLFOX6	25 2 8
6	12-164			CYP2D6 (TARGET-1 study)	25 2 8
7	12-165			MR (3D ASL)	25 2 8
8	09-031-2				25 2 16
9	12-168				25 2 16
10	12-169			Thienopyridine 3 STOPDAPT (XIENCE Prime™)	25 2 16
11	10-050-5			LDL-C versus Intensive Statin Therapy for Hypercholesterolemic Patients with Diabetic Retinopathy EMPATHY Standard	25 2 18
12	12-146			75 002 TS-1 - A feasibility study	25 2 19
13	12-152				25 2 19
14	12-170				25 2 22
15	12-171				25 2 22



No.					
24	12-188			MR (3D ASL)	25 3 30
25	12-189				25 3 30